Welcome to LookChem.com Sign In|Join Free
  • or
5-allyl-4-chloro-6-methyl-2-phenylpyrimidine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

263352-13-2

Post Buying Request

263352-13-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

263352-13-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 263352-13-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,3,3,5 and 2 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 263352-13:
(8*2)+(7*6)+(6*3)+(5*3)+(4*5)+(3*2)+(2*1)+(1*3)=122
122 % 10 = 2
So 263352-13-2 is a valid CAS Registry Number.

263352-13-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-allyl-4-chloro-6-methyl-2-phenylpyrimidine

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:263352-13-2 SDS

263352-13-2Relevant academic research and scientific papers

NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE

-

Page/Page column 37; 38; 41, (2017/08/01)

The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the s

Discovery of selective PDE4B inhibitors

Naganuma, Kenji,Omura, Akifumi,Maekawara, Naomi,Saitoh, Masahiro,Ohkawa, Naoto,Kubota, Takashi,Nagumo, Hiromitsu,Kodama, Toshiyuki,Takemura, Masayoshi,Ohtsuka, Yuji,Nakamura, Junji,Tsujita, Ryuichi,Kawasaki, Koh,Yokoi, Hirotsugu,Kawanishi, Masashi

scheme or table, p. 3174 - 3176 (2010/03/24)

In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivatives afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, a selected compound exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 263352-13-2